You are here

Mol Cancer Res DOI:10.1158/1541-7786.MCR-09-0409

Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2.

Publication TypeJournal Article
Year of Publication2010
AuthorsBoulbes, D, Chen, C-H, Shaikenov, T, Agarwal, NK, Peterson, TR, Addona, TA, Keshishian, H, Carr, SA, Magnuson, MA, Sabatini, DM, Sarbassov, DD
JournalMol Cancer Res
Date Published2010 Jun
KeywordsAnimals, Carrier Proteins, Catalytic Domain, Cell Line, Cell Line, Tumor, Cell Transformation, Neoplastic, Fibroblasts, HeLa Cells, Humans, Intercellular Signaling Peptides and Proteins, Mice, Mice, Knockout, Phosphatidylinositol 3-Kinases, Phosphorylation, Proto-Oncogene Proteins c-akt, Signal Transduction, Threonine, Transcription Factors

In animal cells, growth factors coordinate cell proliferation and survival by regulating the phosphoinositide 3-kinase/Akt signaling pathway. Deregulation of this signaling pathway is common in a variety of human cancers. The PI3K-dependent signaling kinase complex defined as mammalian target of rapamycin complex 2 (mTORC2) functions as a regulatory Ser-473 kinase of Akt. We find that activation of mTORC2 by growth factor signaling is linked to the specific phosphorylation of its component rictor on Thr-1135. The phosphorylation of this site is induced by the growth factor stimulation and expression of the oncogenic forms of ras or PI3K. Rictor phosphorylation is sensitive to the inhibition of PI3K, mTOR, or expression of integrin-linked kinase. The substitution of wild-type rictor with its specific phospho-mutants in rictor null mouse embryonic fibroblasts did not alter the growth factor-dependent phosphorylation of Akt, indicating that the rictor Thr-1135 phosphorylation is not critical in the regulation of the mTORC2 kinase activity. We found that this rictor phosphorylation takes place in the mTORC2-deficient cells, suggesting that this modification might play a role in the regulation of not only mTORC2 but also the mTORC2-independent function of rictor.


Alternate JournalMol. Cancer Res.
PubMed ID20501647
PubMed Central IDPMC2896829
Grant ListR01 CA129105 / CA / NCI NIH HHS / United States
R01 CA133522 / CA / NCI NIH HHS / United States
R01 CA133522-01A1 / CA / NCI NIH HHS / United States
R01 CA133522-02 / CA / NCI NIH HHS / United States